Skip to main content

Table 5 Level 3 variant frequency by gene and number of tests

From: Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

Gene

Number of Variants

Number of Tests

% of Tests

TP53

310

280

0.43

ATM

158

139

0.21

CDKN2A

96

91

0.14

BRCA2

101

90

0.14

PTEN

85

74

0.11

BRCA1

69

61

0.09

PIK3CA

63

56

0.09

TSC2

45

44

0.07

KDR

43

41

0.06

NF1

50

41

0.06

MET

37

37

0.06

RB1

37

37

0.06

PTCH1

37

34

0.05

STK11

30

28

0.04

FBXW7

25

25

0.04

NF2

24

24

0.04

NRAS

23

23

0.04

APC

23

22

0.03

TSC1

23

21

0.03

KRAS

19

18

0.03

IDH1

18

17

0.03

CDK4

18

17

0.03

CSF1R

15

14

0.02

EGFR

14

12

0.02

BRAF

13

11

0.02

ERBB2

15

11

0.02

FGFR3

12

10

0.02

FGFR1

10

9

0.01

AKT1

8

8

0.01

SMO

9

8

0.01

MSH2

9

6

0.01

CCND1

6

6

0.01

KIT

7

6

0.01

PIK3R1

6

6

0.01

RET

6

6

0.01

SMARCB1

5

4

0.01

CHEK2

4

4

0.01

CCNE1

4

4

0.01

MYC

4

4

0.01

BAP1

4

4

0.01

ERBB4

3

3

<.01

DDR2

3

3

<.01

FLT3

3

3

<.01

MAP2K1

3

3

<.01

ALK

3

3

<.01

ESR1

2

2

<.01

GNA11

2

2

<.01

ERBB3

2

2

<.01

HRAS

2

2

<.01

ABL1

2

2

<.01

JAK2

2

2

<.01

MTOR

2

2

<.01

MYCL

2

2

<.01

NFE2L2

2

2

<.01

NTRK1

2

2

<.01

MAPK1

2

2

<.01

AR

1

1

<.01

CDK6

1

1

<.01

FGFR2

1

1

<.01

JAK1

1

1

<.01

WT1

1

1

<.01

MDM2

1

1

<.01

NTRK3

1

1

<.01

RAF1

1

1

<.01

SRC

1

1

<.01

IDH2

1

1

<.01